Source:http://linkedlifedata.com/resource/pubmed/id/12736112
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2003-5-8
|
pubmed:abstractText |
No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m(2)/day for a maximum of 24 weeks) +/-MMC (7 mg/m(2) 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1121-8
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:12736112-Adult,
pubmed-meshheading:12736112-Aged,
pubmed-meshheading:12736112-Aged, 80 and over,
pubmed-meshheading:12736112-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12736112-Disease-Free Survival,
pubmed-meshheading:12736112-Female,
pubmed-meshheading:12736112-Fluorouracil,
pubmed-meshheading:12736112-Humans,
pubmed-meshheading:12736112-Infusions, Intravenous,
pubmed-meshheading:12736112-Male,
pubmed-meshheading:12736112-Middle Aged,
pubmed-meshheading:12736112-Mitomycin,
pubmed-meshheading:12736112-Neoplasms, Unknown Primary,
pubmed-meshheading:12736112-Quality of Life,
pubmed-meshheading:12736112-Regression Analysis,
pubmed-meshheading:12736112-Treatment Outcome
|
pubmed:year |
2003
|
pubmed:articleTitle |
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
|
pubmed:affiliation |
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|